Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B GOTTLIEB

Showing results (261-270 of 523) with videos related to

Pageof 53
Sort By:
Dermatology and Therapy|July 11, 2023
Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support ProgramAlice B Gottlieb, Russel Burge, William N Malatestinic, et al.
Journal of Drugs in Dermatology : JDD|December 31, 2004
Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasisAlice B Gottlieb, Kenneth B Gordon, Mark G Lebwohl, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 23, 2018
Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trialsA Blauvelt, K Reich, M Lebwohl, et al.
Journal of Drugs in Dermatology : JDD|August 14, 2014
A randomized, prospective, sham-controlled study of localized narrow-band UVB phototherapy in the treatment of plaque psoriasisAdriane A Levin, Saud Aleissa, Nicole Dumont, et al.
Dermatology and Therapy|July 14, 2021
Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 TrialsRichard B Warren, Alice B Gottlieb, Joseph F Merola, et al.
Journal of Drugs in Dermatology : JDD|March 17, 2017
The International Dermatology Outcome Measures (IDEOM) Initiative: A Review and UpdateScott A Elman, Joseph F Merola, April W Armstrong, et al.
The New England Journal of Medicine|November 25, 2003
Etanercept as monotherapy in patients with psoriasisCraig L Leonardi, Jerold L Powers, Robert T Matheson, et al.
The Journal of Dermatological Treatment|March 8, 2021
Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasisSteven R Feldman, Joseph F Merola, David M Pariser, et al.
Dermatology and Therapy|May 14, 2023
Patient and Physician Perceptions of Psoriatic Disease in the United States: Results from the UPLIFT SurveyJoseph F Merola, Alexis Ogdie, Alice B Gottlieb, et al.
The Journal of Rheumatology|August 5, 2025
Report of the IDEOM Meeting Adjacent to the GRAPPA 2024 Annual MeetingSarah Romanelli, Beth Childs, Vibeke Strand, et al.
Pageof 53

Showing results (261-270 of 523) with videos related to

Sort By:
Pageof 53
Dermatology and Therapy|July 11, 2023
Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support ProgramAlice B Gottlieb, Russel Burge, William N Malatestinic, et al.
Journal of Drugs in Dermatology : JDD|December 31, 2004
Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasisAlice B Gottlieb, Kenneth B Gordon, Mark G Lebwohl, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 23, 2018
Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trialsA Blauvelt, K Reich, M Lebwohl, et al.
Journal of Drugs in Dermatology : JDD|August 14, 2014
A randomized, prospective, sham-controlled study of localized narrow-band UVB phototherapy in the treatment of plaque psoriasisAdriane A Levin, Saud Aleissa, Nicole Dumont, et al.
Dermatology and Therapy|July 14, 2021
Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 TrialsRichard B Warren, Alice B Gottlieb, Joseph F Merola, et al.
Journal of Drugs in Dermatology : JDD|March 17, 2017
The International Dermatology Outcome Measures (IDEOM) Initiative: A Review and UpdateScott A Elman, Joseph F Merola, April W Armstrong, et al.
The New England Journal of Medicine|November 25, 2003
Etanercept as monotherapy in patients with psoriasisCraig L Leonardi, Jerold L Powers, Robert T Matheson, et al.
The Journal of Dermatological Treatment|March 8, 2021
Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasisSteven R Feldman, Joseph F Merola, David M Pariser, et al.
Dermatology and Therapy|May 14, 2023
Patient and Physician Perceptions of Psoriatic Disease in the United States: Results from the UPLIFT SurveyJoseph F Merola, Alexis Ogdie, Alice B Gottlieb, et al.
The Journal of Rheumatology|August 5, 2025
Report of the IDEOM Meeting Adjacent to the GRAPPA 2024 Annual MeetingSarah Romanelli, Beth Childs, Vibeke Strand, et al.
Pageof 53